Publication Topic

Tornero-Velez R, Dawson D, East A, Breen M, Brady S, Vallero D, Hubal EC, Wambaugh, J. Using systematic evidence mapping to track the development of toxicokinetic models of PFAS from 2000–2021. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022; doi: 10.23645/epacomptox.19333283.

Hearon SE, Orr AA, Moyer H, Wang M, Tamamis P, Phillips TD. Montmorillonite clay-based sorbents decrease the bioavailability of perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) from soil and their translocation to plants. Abstract 3113, Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

Wang Z, Buser A, Cousins I, Demattio S, Drost W, Johansson O, Ohno K, Patlewicz G, et al. 2021. A new OECD definition for per- and polyfluoroalkyl substances. Environ Sci Technol 55(23):15575-15578; doi: 10.1021/acs.est.1c06896. PMID: 34751569.

Houck KA, Patlewicz G, Richard A, Williams AJ, Smeltz M, Clifton, MS, Wetmore B, Medvedev A, Makarov SS. 2021. Bioactivity profiling of per- and polyfluoroalkyl substances identifies potential toxicity pathways related to molecular structure. Toxicology 457(June 15):152789; doi: 10.1016/j.tox.2021.152789. PMID: 33887376.

Kempisty DM, Racz L. 2021. Forever Chemicals: Environmental, Economic, and Social Equity Concerns with PFAS in the Environment. Routledge, Taylor and Francis Group; ISBN 9780367456405.

Chappell GA, Thompson CM, Wolf JC, Cullen JM, Klaunig JE, Haws LC. 2020. Assessment of the mode of action underlying the effects of GenX in mouse liver and implications for assessing human health risks. Toxicol Pathol 48(3):494–508; doi: 10.1177/0192623320905803. PMID: 32138627.

Haws L (session co-chair). Introduction to “Use of New Approach Methods in Risk Characterization of PFAS: Challenges and Opportunities.” 44^th Annual Winter Meeting, the Toxicology Forum, Tysons, VA, January 2020.

Thompson CM, Ring C, Pham L, Chappell GA, Haws LC. Assessment of the relevance of toxicological findings in the development of an oral reference dose for GenX. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.

Thompson C, Chappell G, Cullen J, Wolf JC, Haws L. Development of an oral reference dose for GenX using the latest toxicological and risk assessment methodologies: Environmental risk assessment of per- and polyfluoroalkyl substances (PFAS). SETAC North America Focused Topic Meeting, Durham, NC, August 2019.

Chappell GA, Thompson CM, Wolf J, Cullen J, Haws LC. Transcriptomic responses in livers of GenX-treated mice demonstrate up-regulation of PPAR signaling and related pathways. Environmental Mutagenesis and Genomics Society, Washington, DC, September 2019.

Thompson CM, Fitch SE, Ring C, Rish W, Cullen JM, Haws LC. 2019. Development of an oral reference dose for the perfluorinated compound GenX. J Appl Toxicol 39(9):1267–1282; doi: 10.1002/jat.3812. PMID: 31215065.

Thompson CM. The useful chemistry of perfluorinated compounds: Managing safety. The sticky subject of non-stick: Regulatory science challenges of per- and poly-fluorinated compounds (PFAS). Texas A&M University Interdisciplinary Faculty of Toxicology Training Program, 2019 Annual Regulatory Science Symposium, College Station, TX, August 2019.

Ring CL, Rish WR, Brorby GL. Prioritization of eight PFAS by population exposure and reference-dose uncertainty. Poster session at SETAC North America Focused Topic Meeting: Environmental Risk Assessment of PFAS, Durham, NC, August 2019.

Borghoff SJ, Fitch S, Huggett D, Wikoff D. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine disrupting properties of perfluorohexanoic acid (PFHxA). Poster at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Patlewicz G, Richard AM, Williams AJ, Grulke CM, Sams R, Lambert J, Noyes P, DeVito MJ, et al. 2019. A chemical category-based prioritization approach for selecting 75 per- and polyfluoroalkyl substances (PFAS) for tiered toxicity and toxicokinetic testing. Environ Health Perspect 127(1):14501; doi: 10.1289/EHP4555. PMID: 30632786.

Borghoff SJ, Fitch S, Rager JE, Huggett D. 2018. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid. Regul Toxicol Pharmacol 99(Nov):168–181; doi: 10.1016/j.yrtph.2018.09.001. PMID: 30240830.

Kempisty DM, Xing Y, Racz L (eds). 2018. Perfluoroalkyl Substances in the Environment: Theory, Practice and Innovation. Taylor and Francis CRC Press: Boca Raton, FL.

Paustenbach DJ, Panko JM, Scott PK, Unice KM. 2007. A methodology for estimating human exposure to perfluorooctanoic acid (PFOA): A retrospective exposure assessment of a community (1951-2003). J Toxicol Environ Health A 70(1):28–57; doi: 10.1080/15287390600748815. PMID: 17162497.

Paustenbach DJ, Panko JM, Scott PK, Unice KM. Retrospective modeling of potential residential exposure to perfluorooctanoic acid (PFOA) releases from a manufacturing facility. Society of Toxicology 45th Annual Meeting, San Diego, CA, March 2006.

Lau C, Thibodeaux JR, Hanson RG, Narotsky MG, Rogers JM, Lindstrom AB, Strynar MJ. 2006. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol Sci 90(2):510–518; doi: 10.1093/toxsci/kfj105. PMID: 16415327.